A comprehensive guide to toxicology in preclinical drug development /:
A Comprehensive Guide to Toxicology in Preclinical Drug Development is designed for toxicologists who need a thorough understanding of the drug development process. This multi-contributed reference will provide a detailed picture of the complex and highly interrelated activities of preclinical toxic...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
London ; Waltham, MA :
Academic Press,
2013.
|
| Subjects: | |
| Online Access: | DE-862 DE-863 DE-862 DE-863 |
| Summary: | A Comprehensive Guide to Toxicology in Preclinical Drug Development is designed for toxicologists who need a thorough understanding of the drug development process. This multi-contributed reference will provide a detailed picture of the complex and highly interrelated activities of preclinical toxicology in both small molecules and biologics. Intended as a comprehensive resource for toxicologists in industry and regulatory settings, as well as directors working in contract resource organizations (CRO), this book will discuss discovery toxicology and the international guidelines for safety evaluation and present both traditional and nontraditional toxicology models. By incorporating the latest research in this area and featuring real-life examples and scenarios, this reference is a complete and practical guide to all aspects of preclinical drug testing. Chapters written by world-renowned contributors who are experts in their fields. Includes the latest research in preclinical drug testing and international guidelines. Covers preclinical toxicology in small molecules and biologics in one single source. Incorporates real-life case studies and examples and offers readers a practical resource that outlines day-to-day activities and experiences in preclinical toxicology. |
| Item Description: | Title from pdf title page (viewed October 31, 2012). |
| Physical Description: | 1 online resource (xvi, 885 pages) : illustrations |
| Bibliography: | Includes bibliographical references and index. |
| ISBN: | 1283706504 9781283706506 9780123878168 0123878160 |
Staff View
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn815520350 | ||
| 003 | OCoLC | ||
| 005 | 20250103110447.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 121031s2013 enka ob 001 0 eng d | ||
| 010 | |a 2013444252 | ||
| 040 | |a OPELS |b eng |e rda |e pn |c OPELS |d CUX |d UKMGB |d OCLCQ |d IDEBK |d CHVBK |d OCLCF |d CDX |d OCLCQ |d USU |d OCLCO |d COCUF |d AGLDB |d E7B |d YDXCP |d N$T |d EBLCP |d DEBSZ |d NRC |d ICA |d MERUC |d FEM |d LOA |d K6U |d STF |d OCLCQ |d OCLCO |d OCLCQ |d ZCU |d OCLCO |d OCLCA |d U3W |d OCLCA |d D6H |d OCLCO |d VTS |d OCLCO |d ICG |d BTN |d AUW |d MHW |d INTCL |d SNK |d AU@ |d OCLCO |d OCLCQ |d WYU |d OCLCO |d OCLCA |d VT2 |d OCLCO |d LEAUB |d OCLCO |d DKC |d OCLCO |d OCLCQ |d OCLCO |d UX1 |d OCLCQ |d OCLCA |d OCLCO |d OCL |d HNC |d OCLCQ |d OCLCO |d OCLCQ |d OCLCL |d TMA |d OCLCQ |d SXB |d OCLCQ | ||
| 016 | 7 | |a 101600769 |2 DNLM | |
| 016 | 7 | |a 016209912 |2 Uk | |
| 019 | |a 818867493 |a 819506171 |a 820818932 |a 823134542 |a 960439333 |a 960738864 |a 968109050 |a 969021425 |a 972505722 |a 984782087 |a 1081256286 |a 1228554751 | ||
| 020 | |a 1283706504 | ||
| 020 | |a 9781283706506 | ||
| 020 | |a 9780123878168 | ||
| 020 | |a 0123878160 | ||
| 020 | |z 9780123878151 |q (p-ISBN) | ||
| 020 | |z 0123878152 |q (p-ISBN) | ||
| 035 | |a (OCoLC)815520350 |z (OCoLC)818867493 |z (OCoLC)819506171 |z (OCoLC)820818932 |z (OCoLC)823134542 |z (OCoLC)960439333 |z (OCoLC)960738864 |z (OCoLC)968109050 |z (OCoLC)969021425 |z (OCoLC)972505722 |z (OCoLC)984782087 |z (OCoLC)1081256286 |z (OCoLC)1228554751 | ||
| 050 | 4 | |a RA1238 |b .C66 2013 | |
| 060 | 4 | |a 2013 A-659 | |
| 060 | 4 | |a QV 771 | |
| 072 | 7 | |a MED |x 023000 |2 bisacsh | |
| 072 | 7 | |a MED |x 058170 |2 bisacsh | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 072 | 7 | |a MED |x 072000 |2 bisacsh | |
| 082 | 7 | |a 615.1/9 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 2 | |a A comprehensive guide to toxicology in preclinical drug development / |c edited by Ali S. Faqi. |
| 264 | 1 | |a London ; |a Waltham, MA : |b Academic Press, |c 2013. | |
| 300 | |a 1 online resource (xvi, 885 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |2 rda | ||
| 500 | |a Title from pdf title page (viewed October 31, 2012). | ||
| 504 | |a Includes bibliographical references and index. | ||
| 520 | |a A Comprehensive Guide to Toxicology in Preclinical Drug Development is designed for toxicologists who need a thorough understanding of the drug development process. This multi-contributed reference will provide a detailed picture of the complex and highly interrelated activities of preclinical toxicology in both small molecules and biologics. Intended as a comprehensive resource for toxicologists in industry and regulatory settings, as well as directors working in contract resource organizations (CRO), this book will discuss discovery toxicology and the international guidelines for safety evaluation and present both traditional and nontraditional toxicology models. By incorporating the latest research in this area and featuring real-life examples and scenarios, this reference is a complete and practical guide to all aspects of preclinical drug testing. Chapters written by world-renowned contributors who are experts in their fields. Includes the latest research in preclinical drug testing and international guidelines. Covers preclinical toxicology in small molecules and biologics in one single source. Incorporates real-life case studies and examples and offers readers a practical resource that outlines day-to-day activities and experiences in preclinical toxicology. | ||
| 505 | 0 | |a Front Cover; A Comprehensive Guide to Toxicology in Preclinical Drug Development; Copyright; Dedication; Contents; Foreword; Contributors; Chapter1 -- Introduction; Chapter2 -- ADME in Drug Discovery; INTRODUCTION; ADME; USE OF PRECLINICAL ADME DATA; TWO EVOLVING TECHNOLOGIES IMPACTING ADME IN DRUG DISCOVERY; References; Chapter3 -- Pharmacokinetics and Toxicokinetics; INTRODUCTION; DRUG ADMINISTRATION AND DELIVERY; INTRAVENOUS ADMINISTRATION; ABSORPTION AFTER EXTRAVASCULAR DOSING; CALCULATION OF EXPOSURE-BASED SAFETY MARGINS; PRACTICAL CONSIDERATIONS; CONCLUSIONS; References. | |
| 505 | 8 | |a Chapter4 -- Development of Preclinical Formulations for Toxicology StudiesINTRODUCTION; ANIMAL SPECIES, SAMPLING VOLUMES AND SAMPLING SITES; DOSING ROUTE; DOSING VOLUME; FORMULATION DEVELOPMENT; PHYSICO-CHEMICAL PROPERTY CHARACTERIZATION; SOLUBILITY ENHANCEMENT; SPECIAL DOSAGE FORMS; DECISION TREE; IN VITRO EVALUATION OF THE PERFORMANCE OF A TOXICOLOGICAL STUDY; CASE STUDY; CONCLUDING REMARKS; References; Chapter5 -- Acute, Sub-Acute, Sub-Chronic and Chronic General Toxicity Testing for Preclinical Drug Development; INTRODUCTION. | |
| 505 | 8 | |a REGULATORY CONSIDERATIONS FOR CONDUCTING PRECLINICAL TOXICOLOGY STUDIESGENERAL CONSIDERATIONS FOR THE CONDUCT OF PRECLINICAL TOXICOLOGY STUDIES; STUDY TYPES USED IN THE ASSESSMENT OF GENERAL TOXICOLOGY; SPECIAL CONSIDERATIONS FOR BIOPHARMACEUTICAL SAFETY EVALUATIONS; COMMON PROTOCOL COMPONENTS OF GENERAL TOXICITY ASSESSMENTS IN GLP STUDIES; FINAL THOUGHTS; References; Chapter6 -- Contemporary Practices in Core Safety Pharmacology Assessments; BACKGROUND AND OVERVIEW; SAFETY PHARMACOLOGY AS A REGULATORY SCIENCE; TEMPORAL APPLICATION OF CURRENT EXPERIMENTAL PARADIGMS. | |
| 505 | 8 | |a CARDIOVASCULAR SYSTEM AND MODELS OF SAFETY ASSESSMENTCARDIAC ION CHANNELS AND THE HERG ASSAY; IN VIVO CARDIOVASCULAR SAFETY STUDY; RESPIRATORY SYSTEM AND MODELS OF SAFETY ASSESSMENT; CENTRAL NERVOUS SYSTEM AND MODELS OF SAFETY ASSESSMENT; APPROACHES TO TIER I CNS SAFETY EVALUATION; EVALUATING CNS SAFETY; References; Chapter7 -- Genetic Toxicology Testing; INTRODUCTION; THE CONCEPT OF THRESHOLDS; GENETIC TOXICITY TESTING TO SUPPORT CLINICAL TRIALS; THE SENSITIVITY AND SPECIFICITY OF IN VITRO ASSAYS; IN VIVO CORE TESTS; OTHER IN VIVO TESTS FOR GENOTOXICITY. | |
| 505 | 8 | |a ADDITIONAL TESTS INDICATING GENOTOXICITYGENETOX TESTING STRATEGY: DISCOVERY THROUGH DEVELOPMENT; CONCLUDING REMARKS AND FUTURE DIRECTIONS; References; Chapter8 -- Clinical Pathology; INTRODUCTION; CORE CLINICAL PATHOLOGY TESTING; HEMATOLOGY; CYTOLOGICAL EVALUATION OF BONE MARROW; EMERGING BIOMARKERS AND APPLICATION WITHIN THE CLINICAL PATHOLOGY LABORATORY; CLINICAL PATHOLOGY INDICATORS OF TARGET ORGAN TOXICITY; INTERPRETATION OF CLINICAL PATHOLOGY DATA IN PRECLINICAL SAFETY STUDIES; References; Chapter9 -- Best Practice in Toxicological Pathology; INTRODUCTION. | |
| 650 | 0 | |a Drugs |x Toxicology. |0 http://id.loc.gov/authorities/subjects/sh85039757 | |
| 650 | 0 | |a Drug development. |0 http://id.loc.gov/authorities/subjects/sh97007921 | |
| 650 | 0 | |a Clinical toxicology. |0 http://id.loc.gov/authorities/subjects/sh2003008451 | |
| 650 | 0 | |a Drugs |x Side effects. |0 http://id.loc.gov/authorities/subjects/sh85039746 | |
| 650 | 1 | 2 | |a Drug-Related Side Effects and Adverse Reactions |
| 650 | 2 | 2 | |a Drug Discovery |
| 650 | 6 | |a Médicaments |x Toxicologie. | |
| 650 | 6 | |a Médicaments |x Développement. | |
| 650 | 6 | |a Toxicologie clinique. | |
| 650 | 6 | |a Médicaments |x Effets secondaires. | |
| 650 | 7 | |a MEDICAL |x Drug Guides. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Nursing |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Pharmacy. |2 bisacsh | |
| 650 | 7 | |a Drugs |x Side effects |2 fast | |
| 650 | 7 | |a Clinical toxicology |2 fast | |
| 650 | 7 | |a Drug development |2 fast | |
| 650 | 7 | |a Drugs |x Toxicology |2 fast | |
| 700 | 1 | |a Faqi, Ali S. | |
| 758 | |i has work: |a A Comprehensive Guide to Toxicology in Preclinical Drug Development [recurso electrónico] (Text) |1 https://id.oclc.org/worldcat/entity/E39PCYYDjG9DMJDmk8fDp47qBd |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Faqi, Ali S. |t A Comprehensive Guide to Toxicology in Preclinical Drug Development. |d Burlington : Elsevier Science, ©2012 |z 9780123878151 |
| 966 | 4 | 0 | |l DE-862 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=485040 |3 Volltext |
| 966 | 4 | 0 | |l DE-863 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=485040 |3 Volltext |
| 966 | 4 | 0 | |l DE-862 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://www.sciencedirect.com/science/book/9780123878151 |3 Volltext |
| 966 | 4 | 0 | |l DE-863 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://www.sciencedirect.com/science/book/9780123878151 |3 Volltext |
| 938 | |a Coutts Information Services |b COUT |n 24118787 |c 199.95 USD | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL1048853 | ||
| 938 | |a ebrary |b EBRY |n ebr10617459 | ||
| 938 | |a EBSCOhost |b EBSC |n 485040 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n cis24118787 | ||
| 938 | |a YBP Library Services |b YANK |n 9892163 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-862 | ||
| 049 | |a DE-863 | ||
Record in the Search Index
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn815520350 |
|---|---|
| _version_ | 1829094940118876160 |
| adam_text | |
| any_adam_object | |
| author2 | Faqi, Ali S. |
| author2_role | |
| author2_variant | a s f as asf |
| author_facet | Faqi, Ali S. |
| author_sort | Faqi, Ali S. |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RA1238 |
| callnumber-raw | RA1238 .C66 2013 |
| callnumber-search | RA1238 .C66 2013 |
| callnumber-sort | RA 41238 C66 42013 |
| callnumber-subject | RA - Public Medicine |
| collection | ZDB-4-EBA |
| contents | Front Cover; A Comprehensive Guide to Toxicology in Preclinical Drug Development; Copyright; Dedication; Contents; Foreword; Contributors; Chapter1 -- Introduction; Chapter2 -- ADME in Drug Discovery; INTRODUCTION; ADME; USE OF PRECLINICAL ADME DATA; TWO EVOLVING TECHNOLOGIES IMPACTING ADME IN DRUG DISCOVERY; References; Chapter3 -- Pharmacokinetics and Toxicokinetics; INTRODUCTION; DRUG ADMINISTRATION AND DELIVERY; INTRAVENOUS ADMINISTRATION; ABSORPTION AFTER EXTRAVASCULAR DOSING; CALCULATION OF EXPOSURE-BASED SAFETY MARGINS; PRACTICAL CONSIDERATIONS; CONCLUSIONS; References. Chapter4 -- Development of Preclinical Formulations for Toxicology StudiesINTRODUCTION; ANIMAL SPECIES, SAMPLING VOLUMES AND SAMPLING SITES; DOSING ROUTE; DOSING VOLUME; FORMULATION DEVELOPMENT; PHYSICO-CHEMICAL PROPERTY CHARACTERIZATION; SOLUBILITY ENHANCEMENT; SPECIAL DOSAGE FORMS; DECISION TREE; IN VITRO EVALUATION OF THE PERFORMANCE OF A TOXICOLOGICAL STUDY; CASE STUDY; CONCLUDING REMARKS; References; Chapter5 -- Acute, Sub-Acute, Sub-Chronic and Chronic General Toxicity Testing for Preclinical Drug Development; INTRODUCTION. REGULATORY CONSIDERATIONS FOR CONDUCTING PRECLINICAL TOXICOLOGY STUDIESGENERAL CONSIDERATIONS FOR THE CONDUCT OF PRECLINICAL TOXICOLOGY STUDIES; STUDY TYPES USED IN THE ASSESSMENT OF GENERAL TOXICOLOGY; SPECIAL CONSIDERATIONS FOR BIOPHARMACEUTICAL SAFETY EVALUATIONS; COMMON PROTOCOL COMPONENTS OF GENERAL TOXICITY ASSESSMENTS IN GLP STUDIES; FINAL THOUGHTS; References; Chapter6 -- Contemporary Practices in Core Safety Pharmacology Assessments; BACKGROUND AND OVERVIEW; SAFETY PHARMACOLOGY AS A REGULATORY SCIENCE; TEMPORAL APPLICATION OF CURRENT EXPERIMENTAL PARADIGMS. CARDIOVASCULAR SYSTEM AND MODELS OF SAFETY ASSESSMENTCARDIAC ION CHANNELS AND THE HERG ASSAY; IN VIVO CARDIOVASCULAR SAFETY STUDY; RESPIRATORY SYSTEM AND MODELS OF SAFETY ASSESSMENT; CENTRAL NERVOUS SYSTEM AND MODELS OF SAFETY ASSESSMENT; APPROACHES TO TIER I CNS SAFETY EVALUATION; EVALUATING CNS SAFETY; References; Chapter7 -- Genetic Toxicology Testing; INTRODUCTION; THE CONCEPT OF THRESHOLDS; GENETIC TOXICITY TESTING TO SUPPORT CLINICAL TRIALS; THE SENSITIVITY AND SPECIFICITY OF IN VITRO ASSAYS; IN VIVO CORE TESTS; OTHER IN VIVO TESTS FOR GENOTOXICITY. ADDITIONAL TESTS INDICATING GENOTOXICITYGENETOX TESTING STRATEGY: DISCOVERY THROUGH DEVELOPMENT; CONCLUDING REMARKS AND FUTURE DIRECTIONS; References; Chapter8 -- Clinical Pathology; INTRODUCTION; CORE CLINICAL PATHOLOGY TESTING; HEMATOLOGY; CYTOLOGICAL EVALUATION OF BONE MARROW; EMERGING BIOMARKERS AND APPLICATION WITHIN THE CLINICAL PATHOLOGY LABORATORY; CLINICAL PATHOLOGY INDICATORS OF TARGET ORGAN TOXICITY; INTERPRETATION OF CLINICAL PATHOLOGY DATA IN PRECLINICAL SAFETY STUDIES; References; Chapter9 -- Best Practice in Toxicological Pathology; INTRODUCTION. |
| ctrlnum | (OCoLC)815520350 |
| dewey-full | 615.1/9 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.1/9 |
| dewey-search | 615.1/9 |
| dewey-sort | 3615.1 19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>08340cam a2200889 i 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn815520350</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20250103110447.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">121031s2013 enka ob 001 0 eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a"> 2013444252</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">OPELS</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">OPELS</subfield><subfield code="d">CUX</subfield><subfield code="d">UKMGB</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">IDEBK</subfield><subfield code="d">CHVBK</subfield><subfield code="d">OCLCF</subfield><subfield code="d">CDX</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">USU</subfield><subfield code="d">OCLCO</subfield><subfield code="d">COCUF</subfield><subfield code="d">AGLDB</subfield><subfield code="d">E7B</subfield><subfield code="d">YDXCP</subfield><subfield code="d">N$T</subfield><subfield code="d">EBLCP</subfield><subfield code="d">DEBSZ</subfield><subfield code="d">NRC</subfield><subfield code="d">ICA</subfield><subfield code="d">MERUC</subfield><subfield code="d">FEM</subfield><subfield code="d">LOA</subfield><subfield code="d">K6U</subfield><subfield code="d">STF</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">ZCU</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">U3W</subfield><subfield code="d">OCLCA</subfield><subfield code="d">D6H</subfield><subfield code="d">OCLCO</subfield><subfield code="d">VTS</subfield><subfield code="d">OCLCO</subfield><subfield code="d">ICG</subfield><subfield code="d">BTN</subfield><subfield code="d">AUW</subfield><subfield code="d">MHW</subfield><subfield code="d">INTCL</subfield><subfield code="d">SNK</subfield><subfield code="d">AU@</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">WYU</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">VT2</subfield><subfield code="d">OCLCO</subfield><subfield code="d">LEAUB</subfield><subfield code="d">OCLCO</subfield><subfield code="d">DKC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">UX1</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCL</subfield><subfield code="d">HNC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCL</subfield><subfield code="d">TMA</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">SXB</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">101600769</subfield><subfield code="2">DNLM</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">016209912</subfield><subfield code="2">Uk</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">818867493</subfield><subfield code="a">819506171</subfield><subfield code="a">820818932</subfield><subfield code="a">823134542</subfield><subfield code="a">960439333</subfield><subfield code="a">960738864</subfield><subfield code="a">968109050</subfield><subfield code="a">969021425</subfield><subfield code="a">972505722</subfield><subfield code="a">984782087</subfield><subfield code="a">1081256286</subfield><subfield code="a">1228554751</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1283706504</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781283706506</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780123878168</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0123878160</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780123878151</subfield><subfield code="q">(p-ISBN)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">0123878152</subfield><subfield code="q">(p-ISBN)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)815520350</subfield><subfield code="z">(OCoLC)818867493</subfield><subfield code="z">(OCoLC)819506171</subfield><subfield code="z">(OCoLC)820818932</subfield><subfield code="z">(OCoLC)823134542</subfield><subfield code="z">(OCoLC)960439333</subfield><subfield code="z">(OCoLC)960738864</subfield><subfield code="z">(OCoLC)968109050</subfield><subfield code="z">(OCoLC)969021425</subfield><subfield code="z">(OCoLC)972505722</subfield><subfield code="z">(OCoLC)984782087</subfield><subfield code="z">(OCoLC)1081256286</subfield><subfield code="z">(OCoLC)1228554751</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RA1238</subfield><subfield code="b">.C66 2013</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">2013 A-659</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QV 771</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">023000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">058170</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">071000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">072000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.1/9</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="2"><subfield code="a">A comprehensive guide to toxicology in preclinical drug development /</subfield><subfield code="c">edited by Ali S. Faqi.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London ;</subfield><subfield code="a">Waltham, MA :</subfield><subfield code="b">Academic Press,</subfield><subfield code="c">2013.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xvi, 885 pages) :</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="2">rda</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Title from pdf title page (viewed October 31, 2012).</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A Comprehensive Guide to Toxicology in Preclinical Drug Development is designed for toxicologists who need a thorough understanding of the drug development process. This multi-contributed reference will provide a detailed picture of the complex and highly interrelated activities of preclinical toxicology in both small molecules and biologics. Intended as a comprehensive resource for toxicologists in industry and regulatory settings, as well as directors working in contract resource organizations (CRO), this book will discuss discovery toxicology and the international guidelines for safety evaluation and present both traditional and nontraditional toxicology models. By incorporating the latest research in this area and featuring real-life examples and scenarios, this reference is a complete and practical guide to all aspects of preclinical drug testing. Chapters written by world-renowned contributors who are experts in their fields. Includes the latest research in preclinical drug testing and international guidelines. Covers preclinical toxicology in small molecules and biologics in one single source. Incorporates real-life case studies and examples and offers readers a practical resource that outlines day-to-day activities and experiences in preclinical toxicology.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Front Cover; A Comprehensive Guide to Toxicology in Preclinical Drug Development; Copyright; Dedication; Contents; Foreword; Contributors; Chapter1 -- Introduction; Chapter2 -- ADME in Drug Discovery; INTRODUCTION; ADME; USE OF PRECLINICAL ADME DATA; TWO EVOLVING TECHNOLOGIES IMPACTING ADME IN DRUG DISCOVERY; References; Chapter3 -- Pharmacokinetics and Toxicokinetics; INTRODUCTION; DRUG ADMINISTRATION AND DELIVERY; INTRAVENOUS ADMINISTRATION; ABSORPTION AFTER EXTRAVASCULAR DOSING; CALCULATION OF EXPOSURE-BASED SAFETY MARGINS; PRACTICAL CONSIDERATIONS; CONCLUSIONS; References.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Chapter4 -- Development of Preclinical Formulations for Toxicology StudiesINTRODUCTION; ANIMAL SPECIES, SAMPLING VOLUMES AND SAMPLING SITES; DOSING ROUTE; DOSING VOLUME; FORMULATION DEVELOPMENT; PHYSICO-CHEMICAL PROPERTY CHARACTERIZATION; SOLUBILITY ENHANCEMENT; SPECIAL DOSAGE FORMS; DECISION TREE; IN VITRO EVALUATION OF THE PERFORMANCE OF A TOXICOLOGICAL STUDY; CASE STUDY; CONCLUDING REMARKS; References; Chapter5 -- Acute, Sub-Acute, Sub-Chronic and Chronic General Toxicity Testing for Preclinical Drug Development; INTRODUCTION.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">REGULATORY CONSIDERATIONS FOR CONDUCTING PRECLINICAL TOXICOLOGY STUDIESGENERAL CONSIDERATIONS FOR THE CONDUCT OF PRECLINICAL TOXICOLOGY STUDIES; STUDY TYPES USED IN THE ASSESSMENT OF GENERAL TOXICOLOGY; SPECIAL CONSIDERATIONS FOR BIOPHARMACEUTICAL SAFETY EVALUATIONS; COMMON PROTOCOL COMPONENTS OF GENERAL TOXICITY ASSESSMENTS IN GLP STUDIES; FINAL THOUGHTS; References; Chapter6 -- Contemporary Practices in Core Safety Pharmacology Assessments; BACKGROUND AND OVERVIEW; SAFETY PHARMACOLOGY AS A REGULATORY SCIENCE; TEMPORAL APPLICATION OF CURRENT EXPERIMENTAL PARADIGMS.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">CARDIOVASCULAR SYSTEM AND MODELS OF SAFETY ASSESSMENTCARDIAC ION CHANNELS AND THE HERG ASSAY; IN VIVO CARDIOVASCULAR SAFETY STUDY; RESPIRATORY SYSTEM AND MODELS OF SAFETY ASSESSMENT; CENTRAL NERVOUS SYSTEM AND MODELS OF SAFETY ASSESSMENT; APPROACHES TO TIER I CNS SAFETY EVALUATION; EVALUATING CNS SAFETY; References; Chapter7 -- Genetic Toxicology Testing; INTRODUCTION; THE CONCEPT OF THRESHOLDS; GENETIC TOXICITY TESTING TO SUPPORT CLINICAL TRIALS; THE SENSITIVITY AND SPECIFICITY OF IN VITRO ASSAYS; IN VIVO CORE TESTS; OTHER IN VIVO TESTS FOR GENOTOXICITY.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">ADDITIONAL TESTS INDICATING GENOTOXICITYGENETOX TESTING STRATEGY: DISCOVERY THROUGH DEVELOPMENT; CONCLUDING REMARKS AND FUTURE DIRECTIONS; References; Chapter8 -- Clinical Pathology; INTRODUCTION; CORE CLINICAL PATHOLOGY TESTING; HEMATOLOGY; CYTOLOGICAL EVALUATION OF BONE MARROW; EMERGING BIOMARKERS AND APPLICATION WITHIN THE CLINICAL PATHOLOGY LABORATORY; CLINICAL PATHOLOGY INDICATORS OF TARGET ORGAN TOXICITY; INTERPRETATION OF CLINICAL PATHOLOGY DATA IN PRECLINICAL SAFETY STUDIES; References; Chapter9 -- Best Practice in Toxicological Pathology; INTRODUCTION.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drugs</subfield><subfield code="x">Toxicology.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85039757</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug development.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh97007921</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Clinical toxicology.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh2003008451</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drugs</subfield><subfield code="x">Side effects.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85039746</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Drug-Related Side Effects and Adverse Reactions</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Drug Discovery</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Toxicologie.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Développement.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Toxicologie clinique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Effets secondaires.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Drug Guides.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Nursing</subfield><subfield code="x">Pharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pharmacy.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs</subfield><subfield code="x">Side effects</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical toxicology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug development</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs</subfield><subfield code="x">Toxicology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Faqi, Ali S.</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">A Comprehensive Guide to Toxicology in Preclinical Drug Development [recurso electrónico] (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCYYDjG9DMJDmk8fDp47qBd</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Faqi, Ali S.</subfield><subfield code="t">A Comprehensive Guide to Toxicology in Preclinical Drug Development.</subfield><subfield code="d">Burlington : Elsevier Science, ©2012</subfield><subfield code="z">9780123878151</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-862</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=485040</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-863</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=485040</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-862</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://www.sciencedirect.com/science/book/9780123878151</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-863</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://www.sciencedirect.com/science/book/9780123878151</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Coutts Information Services</subfield><subfield code="b">COUT</subfield><subfield code="n">24118787</subfield><subfield code="c">199.95 USD</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL1048853</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10617459</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">485040</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest MyiLibrary Digital eBook Collection</subfield><subfield code="b">IDEB</subfield><subfield code="n">cis24118787</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">9892163</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-862</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-ocn815520350 |
| illustrated | Illustrated |
| indexdate | 2025-04-11T08:41:06Z |
| institution | BVB |
| isbn | 1283706504 9781283706506 9780123878168 0123878160 |
| language | English |
| lccn | 2013444252 |
| oclc_num | 815520350 |
| open_access_boolean | |
| owner | MAIN DE-862 DE-BY-FWS DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-862 DE-BY-FWS DE-863 DE-BY-FWS |
| physical | 1 online resource (xvi, 885 pages) : illustrations |
| psigel | ZDB-4-EBA FWS_PDA_EBA ZDB-4-EBA |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | Academic Press, |
| record_format | marc |
| spelling | A comprehensive guide to toxicology in preclinical drug development / edited by Ali S. Faqi. London ; Waltham, MA : Academic Press, 2013. 1 online resource (xvi, 885 pages) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier text file rda Title from pdf title page (viewed October 31, 2012). Includes bibliographical references and index. A Comprehensive Guide to Toxicology in Preclinical Drug Development is designed for toxicologists who need a thorough understanding of the drug development process. This multi-contributed reference will provide a detailed picture of the complex and highly interrelated activities of preclinical toxicology in both small molecules and biologics. Intended as a comprehensive resource for toxicologists in industry and regulatory settings, as well as directors working in contract resource organizations (CRO), this book will discuss discovery toxicology and the international guidelines for safety evaluation and present both traditional and nontraditional toxicology models. By incorporating the latest research in this area and featuring real-life examples and scenarios, this reference is a complete and practical guide to all aspects of preclinical drug testing. Chapters written by world-renowned contributors who are experts in their fields. Includes the latest research in preclinical drug testing and international guidelines. Covers preclinical toxicology in small molecules and biologics in one single source. Incorporates real-life case studies and examples and offers readers a practical resource that outlines day-to-day activities and experiences in preclinical toxicology. Front Cover; A Comprehensive Guide to Toxicology in Preclinical Drug Development; Copyright; Dedication; Contents; Foreword; Contributors; Chapter1 -- Introduction; Chapter2 -- ADME in Drug Discovery; INTRODUCTION; ADME; USE OF PRECLINICAL ADME DATA; TWO EVOLVING TECHNOLOGIES IMPACTING ADME IN DRUG DISCOVERY; References; Chapter3 -- Pharmacokinetics and Toxicokinetics; INTRODUCTION; DRUG ADMINISTRATION AND DELIVERY; INTRAVENOUS ADMINISTRATION; ABSORPTION AFTER EXTRAVASCULAR DOSING; CALCULATION OF EXPOSURE-BASED SAFETY MARGINS; PRACTICAL CONSIDERATIONS; CONCLUSIONS; References. Chapter4 -- Development of Preclinical Formulations for Toxicology StudiesINTRODUCTION; ANIMAL SPECIES, SAMPLING VOLUMES AND SAMPLING SITES; DOSING ROUTE; DOSING VOLUME; FORMULATION DEVELOPMENT; PHYSICO-CHEMICAL PROPERTY CHARACTERIZATION; SOLUBILITY ENHANCEMENT; SPECIAL DOSAGE FORMS; DECISION TREE; IN VITRO EVALUATION OF THE PERFORMANCE OF A TOXICOLOGICAL STUDY; CASE STUDY; CONCLUDING REMARKS; References; Chapter5 -- Acute, Sub-Acute, Sub-Chronic and Chronic General Toxicity Testing for Preclinical Drug Development; INTRODUCTION. REGULATORY CONSIDERATIONS FOR CONDUCTING PRECLINICAL TOXICOLOGY STUDIESGENERAL CONSIDERATIONS FOR THE CONDUCT OF PRECLINICAL TOXICOLOGY STUDIES; STUDY TYPES USED IN THE ASSESSMENT OF GENERAL TOXICOLOGY; SPECIAL CONSIDERATIONS FOR BIOPHARMACEUTICAL SAFETY EVALUATIONS; COMMON PROTOCOL COMPONENTS OF GENERAL TOXICITY ASSESSMENTS IN GLP STUDIES; FINAL THOUGHTS; References; Chapter6 -- Contemporary Practices in Core Safety Pharmacology Assessments; BACKGROUND AND OVERVIEW; SAFETY PHARMACOLOGY AS A REGULATORY SCIENCE; TEMPORAL APPLICATION OF CURRENT EXPERIMENTAL PARADIGMS. CARDIOVASCULAR SYSTEM AND MODELS OF SAFETY ASSESSMENTCARDIAC ION CHANNELS AND THE HERG ASSAY; IN VIVO CARDIOVASCULAR SAFETY STUDY; RESPIRATORY SYSTEM AND MODELS OF SAFETY ASSESSMENT; CENTRAL NERVOUS SYSTEM AND MODELS OF SAFETY ASSESSMENT; APPROACHES TO TIER I CNS SAFETY EVALUATION; EVALUATING CNS SAFETY; References; Chapter7 -- Genetic Toxicology Testing; INTRODUCTION; THE CONCEPT OF THRESHOLDS; GENETIC TOXICITY TESTING TO SUPPORT CLINICAL TRIALS; THE SENSITIVITY AND SPECIFICITY OF IN VITRO ASSAYS; IN VIVO CORE TESTS; OTHER IN VIVO TESTS FOR GENOTOXICITY. ADDITIONAL TESTS INDICATING GENOTOXICITYGENETOX TESTING STRATEGY: DISCOVERY THROUGH DEVELOPMENT; CONCLUDING REMARKS AND FUTURE DIRECTIONS; References; Chapter8 -- Clinical Pathology; INTRODUCTION; CORE CLINICAL PATHOLOGY TESTING; HEMATOLOGY; CYTOLOGICAL EVALUATION OF BONE MARROW; EMERGING BIOMARKERS AND APPLICATION WITHIN THE CLINICAL PATHOLOGY LABORATORY; CLINICAL PATHOLOGY INDICATORS OF TARGET ORGAN TOXICITY; INTERPRETATION OF CLINICAL PATHOLOGY DATA IN PRECLINICAL SAFETY STUDIES; References; Chapter9 -- Best Practice in Toxicological Pathology; INTRODUCTION. Drugs Toxicology. http://id.loc.gov/authorities/subjects/sh85039757 Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Clinical toxicology. http://id.loc.gov/authorities/subjects/sh2003008451 Drugs Side effects. http://id.loc.gov/authorities/subjects/sh85039746 Drug-Related Side Effects and Adverse Reactions Drug Discovery Médicaments Toxicologie. Médicaments Développement. Toxicologie clinique. Médicaments Effets secondaires. MEDICAL Drug Guides. bisacsh MEDICAL Nursing Pharmacology. bisacsh MEDICAL Pharmacology. bisacsh MEDICAL Pharmacy. bisacsh Drugs Side effects fast Clinical toxicology fast Drug development fast Drugs Toxicology fast Faqi, Ali S. has work: A Comprehensive Guide to Toxicology in Preclinical Drug Development [recurso electrónico] (Text) https://id.oclc.org/worldcat/entity/E39PCYYDjG9DMJDmk8fDp47qBd https://id.oclc.org/worldcat/ontology/hasWork Print version: Faqi, Ali S. A Comprehensive Guide to Toxicology in Preclinical Drug Development. Burlington : Elsevier Science, ©2012 9780123878151 |
| spellingShingle | A comprehensive guide to toxicology in preclinical drug development / Front Cover; A Comprehensive Guide to Toxicology in Preclinical Drug Development; Copyright; Dedication; Contents; Foreword; Contributors; Chapter1 -- Introduction; Chapter2 -- ADME in Drug Discovery; INTRODUCTION; ADME; USE OF PRECLINICAL ADME DATA; TWO EVOLVING TECHNOLOGIES IMPACTING ADME IN DRUG DISCOVERY; References; Chapter3 -- Pharmacokinetics and Toxicokinetics; INTRODUCTION; DRUG ADMINISTRATION AND DELIVERY; INTRAVENOUS ADMINISTRATION; ABSORPTION AFTER EXTRAVASCULAR DOSING; CALCULATION OF EXPOSURE-BASED SAFETY MARGINS; PRACTICAL CONSIDERATIONS; CONCLUSIONS; References. Chapter4 -- Development of Preclinical Formulations for Toxicology StudiesINTRODUCTION; ANIMAL SPECIES, SAMPLING VOLUMES AND SAMPLING SITES; DOSING ROUTE; DOSING VOLUME; FORMULATION DEVELOPMENT; PHYSICO-CHEMICAL PROPERTY CHARACTERIZATION; SOLUBILITY ENHANCEMENT; SPECIAL DOSAGE FORMS; DECISION TREE; IN VITRO EVALUATION OF THE PERFORMANCE OF A TOXICOLOGICAL STUDY; CASE STUDY; CONCLUDING REMARKS; References; Chapter5 -- Acute, Sub-Acute, Sub-Chronic and Chronic General Toxicity Testing for Preclinical Drug Development; INTRODUCTION. REGULATORY CONSIDERATIONS FOR CONDUCTING PRECLINICAL TOXICOLOGY STUDIESGENERAL CONSIDERATIONS FOR THE CONDUCT OF PRECLINICAL TOXICOLOGY STUDIES; STUDY TYPES USED IN THE ASSESSMENT OF GENERAL TOXICOLOGY; SPECIAL CONSIDERATIONS FOR BIOPHARMACEUTICAL SAFETY EVALUATIONS; COMMON PROTOCOL COMPONENTS OF GENERAL TOXICITY ASSESSMENTS IN GLP STUDIES; FINAL THOUGHTS; References; Chapter6 -- Contemporary Practices in Core Safety Pharmacology Assessments; BACKGROUND AND OVERVIEW; SAFETY PHARMACOLOGY AS A REGULATORY SCIENCE; TEMPORAL APPLICATION OF CURRENT EXPERIMENTAL PARADIGMS. CARDIOVASCULAR SYSTEM AND MODELS OF SAFETY ASSESSMENTCARDIAC ION CHANNELS AND THE HERG ASSAY; IN VIVO CARDIOVASCULAR SAFETY STUDY; RESPIRATORY SYSTEM AND MODELS OF SAFETY ASSESSMENT; CENTRAL NERVOUS SYSTEM AND MODELS OF SAFETY ASSESSMENT; APPROACHES TO TIER I CNS SAFETY EVALUATION; EVALUATING CNS SAFETY; References; Chapter7 -- Genetic Toxicology Testing; INTRODUCTION; THE CONCEPT OF THRESHOLDS; GENETIC TOXICITY TESTING TO SUPPORT CLINICAL TRIALS; THE SENSITIVITY AND SPECIFICITY OF IN VITRO ASSAYS; IN VIVO CORE TESTS; OTHER IN VIVO TESTS FOR GENOTOXICITY. ADDITIONAL TESTS INDICATING GENOTOXICITYGENETOX TESTING STRATEGY: DISCOVERY THROUGH DEVELOPMENT; CONCLUDING REMARKS AND FUTURE DIRECTIONS; References; Chapter8 -- Clinical Pathology; INTRODUCTION; CORE CLINICAL PATHOLOGY TESTING; HEMATOLOGY; CYTOLOGICAL EVALUATION OF BONE MARROW; EMERGING BIOMARKERS AND APPLICATION WITHIN THE CLINICAL PATHOLOGY LABORATORY; CLINICAL PATHOLOGY INDICATORS OF TARGET ORGAN TOXICITY; INTERPRETATION OF CLINICAL PATHOLOGY DATA IN PRECLINICAL SAFETY STUDIES; References; Chapter9 -- Best Practice in Toxicological Pathology; INTRODUCTION. Drugs Toxicology. http://id.loc.gov/authorities/subjects/sh85039757 Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Clinical toxicology. http://id.loc.gov/authorities/subjects/sh2003008451 Drugs Side effects. http://id.loc.gov/authorities/subjects/sh85039746 Drug-Related Side Effects and Adverse Reactions Drug Discovery Médicaments Toxicologie. Médicaments Développement. Toxicologie clinique. Médicaments Effets secondaires. MEDICAL Drug Guides. bisacsh MEDICAL Nursing Pharmacology. bisacsh MEDICAL Pharmacology. bisacsh MEDICAL Pharmacy. bisacsh Drugs Side effects fast Clinical toxicology fast Drug development fast Drugs Toxicology fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85039757 http://id.loc.gov/authorities/subjects/sh97007921 http://id.loc.gov/authorities/subjects/sh2003008451 http://id.loc.gov/authorities/subjects/sh85039746 |
| title | A comprehensive guide to toxicology in preclinical drug development / |
| title_auth | A comprehensive guide to toxicology in preclinical drug development / |
| title_exact_search | A comprehensive guide to toxicology in preclinical drug development / |
| title_full | A comprehensive guide to toxicology in preclinical drug development / edited by Ali S. Faqi. |
| title_fullStr | A comprehensive guide to toxicology in preclinical drug development / edited by Ali S. Faqi. |
| title_full_unstemmed | A comprehensive guide to toxicology in preclinical drug development / edited by Ali S. Faqi. |
| title_short | A comprehensive guide to toxicology in preclinical drug development / |
| title_sort | comprehensive guide to toxicology in preclinical drug development |
| topic | Drugs Toxicology. http://id.loc.gov/authorities/subjects/sh85039757 Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Clinical toxicology. http://id.loc.gov/authorities/subjects/sh2003008451 Drugs Side effects. http://id.loc.gov/authorities/subjects/sh85039746 Drug-Related Side Effects and Adverse Reactions Drug Discovery Médicaments Toxicologie. Médicaments Développement. Toxicologie clinique. Médicaments Effets secondaires. MEDICAL Drug Guides. bisacsh MEDICAL Nursing Pharmacology. bisacsh MEDICAL Pharmacology. bisacsh MEDICAL Pharmacy. bisacsh Drugs Side effects fast Clinical toxicology fast Drug development fast Drugs Toxicology fast |
| topic_facet | Drugs Toxicology. Drug development. Clinical toxicology. Drugs Side effects. Drug-Related Side Effects and Adverse Reactions Drug Discovery Médicaments Toxicologie. Médicaments Développement. Toxicologie clinique. Médicaments Effets secondaires. MEDICAL Drug Guides. MEDICAL Nursing Pharmacology. MEDICAL Pharmacology. MEDICAL Pharmacy. Drugs Side effects Clinical toxicology Drug development Drugs Toxicology |
| work_keys_str_mv | AT faqialis acomprehensiveguidetotoxicologyinpreclinicaldrugdevelopment AT faqialis comprehensiveguidetotoxicologyinpreclinicaldrugdevelopment |